At the moment, there are four vaccines on the European market. On Monday it could be five.
This Monday the European Medicines Agency will decide on Novavax, which could be the fifth covid-19 vaccine in the European market. The dose has 5 micrograms of protein and 50 micrograms of adjuvant, an additive that promotes the response in the immune system. It can be stored, handled and distributed at temperatures between 1.7 and 7.8 degrees Celsius.
Such a decision comes a year after the approval of Pfizer, the spearhead of the European vaccination campaign. On December 21, 2020, the news came that had the world on edge: EMA scientists gave their go-ahead to the vaccine developed by the pharmaceutical companies Pfizer and BioNTech.
–
This was the first vaccine against covid-19 that reached the European market, which was a light at the end of the tunnel for doctors and a large part of the population who since March 2020 struggled with the uncertainty of a virus capable of putting in check the globalized world.
The following months, three more vaccines were approved: Moderna (January 6), AstraZeneca (January 29) and Janssen (March 11), accompanied by a scientific race to develop treatments for COVID-19.
–
The advance of the Omicron variant tarnishes the first anniversary of vaccines against covid-19.
– – .
